The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

The persistence of Mycobacterium tuberculosis despite prolonged chemotherapy represents a major obstacle for the control of tuberculosis. The mechanisms used by Mtb to persist in a quiescent state are largely unknown. Chemical genetic and genetic approaches were used here to study the physiology of hypoxic nonreplicating mycobacteria. We found that the intracellular concentration of ATP is five to six times lower in hypoxic nonreplicating Mtb cells compared with aerobic replicating bacteria, making them exquisitely sensitive to any further depletion. We show that de novo ATP synthesis is essential for the viability of hypoxic nonreplicating mycobacteria, requiring the cytoplasmic membrane to be fully energized. In addition, the anaerobic electron transport chain was demonstrated to be necessary for the generation of the protonmotive force. Surprisingly, the alternate ndh-2, but not -1, was shown to be the electron donor to the electron transport chain and to be essential to replenish the [NAD+] pool in hypoxic nonreplicating Mtb. Finally, we describe here the high bactericidal activity of the F0F1 ATP synthase inhibitor R207910 on hypoxic nonreplicating bacteria, supporting the potential of this drug candidate for shortening the time of tuberculosis therapy.

[1]  Tuberculosis. Scientific blueprint for tuberculosis drug development. , 2001, Tuberculosis.

[2]  T. Parish,et al.  Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. , 2000, Microbiology.

[3]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[4]  D. Sherman,et al.  Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Goldman.  Enzyme systems in the mycobacteria. VII. Purification, properties and mechanism of action of the alanine dehydrogenase. , 1959, Biochimica et biophysica acta.

[6]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[7]  L G Wayne,et al.  Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions , 1982, Infection and immunity.

[8]  P. Brennan.  Foreword from the Co-Editor-in-Chief , 2001 .

[9]  C. Sohaskey,et al.  Nonreplicating persistence of mycobacterium tuberculosis. , 2001, Annual review of microbiology.

[10]  H. Rottenberg.  The measurement of membrane potential and deltapH in cells, organelles, and vesicles. , 1979, Methods in enzymology.

[11]  R. Cox,et al.  Growth regulation in the mycobacterial cell. , 2007, Current molecular medicine.

[12]  Dirk Bald,et al.  Diarylquinolines target subunit c of mycobacterial ATP synthase. , 2007, Nature chemical biology.

[13]  D. White.  The Physiology and Biochemistry of Prokaryotes , 1999 .

[14]  E. Rubin,et al.  Differential Antibiotic Susceptibilities of Starved Mycobacterium tuberculosis Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[15]  Ying Zhang,et al.  Susceptibility of Mycobacterium tuberculosis to weak acids. , 2003, The Journal of antimicrobial chemotherapy.

[16]  Martin Tompa,et al.  Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis , 2003, Molecular microbiology.

[17]  H. Rubin,et al.  Steady-state Kinetics and Inhibitory Action of Antitubercular Phenothiazines on Mycobacterium tuberculosis Type-II NADH-Menaquinone Oxidoreductase (NDH-2)* , 2006, Journal of Biological Chemistry.

[18]  G. Unden,et al.  Generation of a proton potential by succinate dehydrogenase of Bacillus subtilis functioning as a fumarate reductase. , 2001, European journal of biochemistry.

[19]  Tanya Parish,et al.  Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. , 2004, Tuberculosis.

[20]  Yang Liu,et al.  Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages , 2003, The Journal of experimental medicine.

[21]  H. Rubin,et al.  Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Unden,et al.  Requirement for the proton-pumping NADH dehydrogenase I of Escherichia coli in respiration of NADH to fumarate and its bioenergetic implications. , 1997, European journal of biochemistry.

[23]  Dirk Schnappinger,et al.  Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Mitchison.  Shortening the treatment of tuberculosis , 2005, Nature Biotechnology.

[25]  J. Casida,et al.  Reaction sites of rotenone, piericidin A, and amytal in relation to the nonheme iron components of NADH dehydrogenase. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Andries,et al.  Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.

[27]  T. Dick,et al.  Oxygen Depletion-Induced Dormancy in Mycobacterium bovis BCG , 1999, Journal of bacteriology.

[28]  G. Schoolnik,et al.  Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. , 2004, Tuberculosis.

[29]  Clifton E. Barry,et al.  Tuberculosis — metabolism and respiration in the absence of growth , 2005, Nature Reviews Microbiology.

[30]  W. Jacobs,et al.  Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. , 2002, Microbiology.

[31]  D. Sherman,et al.  Two Sensor Kinases Contribute to the Hypoxic Response of Mycobacterium tuberculosis* , 2004, Journal of Biological Chemistry.

[32]  L. G. Wayne.  Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. , 2015, The American review of respiratory disease.

[33]  G. Cook,et al.  Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG. , 2001, Microbiology.

[34]  Thomas Dick,et al.  Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy , 2002, Journal of bacteriology.

[35]  D. Clark,et al.  Role of NAD in regulating the adhE gene of Escherichia coli , 1996, Journal of bacteriology.

[36]  C. Vilchèze,et al.  Altered NADH/NAD+ Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria , 2005, Antimicrobial Agents and Chemotherapy.

[37]  T. Dick.  Dormant tubercle bacilli: the key to more effective TB chemotherapy? , 2001, The Journal of antimicrobial chemotherapy.

[38]  J. Hinds,et al.  Enhanced gene replacement in mycobacteria. , 1999, Microbiology.

[39]  D. Goldman.  Enzyme systems in the mycobacteria. I. The isocitric dehydrogenase. , 1956, Journal of bacteriology.

[40]  H. Rubin,et al.  Type II NADH: menaquinone oxidoreductase of Mycobacterium tuberculosis. , 2007, Infectious disorders drug targets.

[41]  C. Bernofsky,et al.  An improved cycling assay for nicotinamide adenine dinucleotide. , 1973, Analytical biochemistry.

[42]  B. Hutter,et al.  Properties of the 40 kDa antigen of Mycobacterium tuberculosis, a functional L-alanine dehydrogenase. , 1999, The Biochemical journal.

[43]  M. Teixeira,et al.  New Insights into Type II NAD(P)H:Quinone Oxidoreductases , 2004, Microbiology and Molecular Biology Reviews.

[44]  Paul Singleton,et al.  Bacteria in biology, biotechnology, and medicine , 1995 .

[45]  H. Shapiro,et al.  Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. , 1999, Cytometry.